Bajaj Finserv Healthcare Fund
Direct · GrowthAI Summary
Bajaj Finserv Healthcare Fund delivered a 1Y SIP XIRR of 11.19%, trailing the category average SIP XIRR of 14.1%. Against the NIFTY 50, however, the fund shows strong outperformance with a 1Y CAGR of 21.86% versus the benchmark's -2.9%, generating alpha of 20.78%. Calendar year returns have been uneven, with 23.57% in 2026 but near-flat results in 2024 (0.18%) and 2025 (-2.96%).
The fund exhibits low beta of 0.58 against the NIFTY 50, with downside capture of 45% in the 1Y window, indicating it has fallen far less than the benchmark in declining markets. The maximum drawdown is modest at -0.16% with a 57-day duration, though recovery took 262 days and there have been 2 drawdown events exceeding 10%. The 1Y Calmar ratio of 0.58 suggests moderate risk-adjusted efficiency relative to its drawdown experience.
The portfolio is heavily concentrated in healthcare, with Pharmaceuticals & Biotechnology at 60.5% and Healthcare Services at 18.4% of assets. Divi's Laboratories (9.67%) and Sun Pharmaceutical (8.87%) are the top positions, and the top 10 holdings account for roughly 58% of the 29-stock portfolio. This focused approach is typical of a sectoral fund but leaves investors fully exposed to healthcare sector cycles.
The fund's 1Y SIP XIRR of 11.19% lags the category average of 14.1%, placing it below peers on the primary return metric. Its lump-sum performance versus the NIFTY 50 is stronger, with positive alpha across 1Y (20.78%) and 3Y (3.41%) windows, though alpha turns negative beyond 10 years. The inconsistent calendar year returns suggest performance has been dependent on healthcare sector momentum rather than steady outperformance.
This fund is suitable for investors who already hold a diversified core portfolio and want a tactical satellite allocation to the healthcare theme. A horizon of at least 5-7 years is advisable given sector cyclicality and the fund's weak long-horizon alpha versus the benchmark. Investors should have high risk tolerance, as sectoral funds can underperform significantly during unfavorable sector cycles.
- Strong 1Y alpha of 20.78% against the NIFTY 50, with fund CAGR of 21.86% versus benchmark's -2.9%
- Low beta of 0.58 and downside capture of 45% in the 1Y window, offering meaningful downside protection versus the benchmark
- Exposure to quality healthcare leaders including Divi's Laboratories and Sun Pharmaceutical, with a reasonable 29-stock portfolio
- 1Y SIP XIRR of 11.19% trails the category average SIP XIRR of 14.1%
- Extreme sector concentration, with 78.9% in pharma and healthcare services, magnifies sector-specific risk
- Negative alpha over 10Y (-0.67%) and 15Y (-1.24%) windows versus the NIFTY 50, indicating weak long-term lump-sum relative performance
Generated on 06-09-2026, 2:49 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.45 L | 11.2% | -11.5% | 43.0% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 11.2% | 14.4% | 14.1% | -3.2% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 9.2% | 10.0% | -4.2% | 25.4% | 0.38 | 0.75 | 85% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +20.78 | 0.58 | 74.1% | 45.0% | 21.9% | -2.9% |
| 3 Years | +3.41 | 0.64 | 74.3% | 60.3% | 6.2% | 0.7% |
| 5 Years | +1.05 | 0.64 | 74.3% | 60.3% | 3.7% | 0.4% |
| 7 Years | +0.05 | 0.64 | 74.3% | 60.3% | 2.6% | 0.3% |
| 10 Years | -0.67 | 0.64 | 74.3% | 60.3% | 1.8% | 0.2% |
| 12 Years | -0.96 | 0.64 | 74.3% | 60.3% | 1.5% | 0.2% |
| 15 Years | -1.24 | 0.64 | 74.3% | 60.3% | 1.2% | 0.1% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Divi's Laboratories Limited | 9.67% |
| 2 | Sun Pharmaceutical Industries Limited | 8.87% |
| 3 | Apollo Hospitals Enterprise Limited | 6.50% |
| 4 | Aurobindo Pharma Limited | 6.13% |
| 5 | Rubicon Research Limited | 6.01% |
| 6 | Torrent Pharmaceuticals Limited | 5.48% |
| 7 | Neuland Laboratories Limited | 4.42% |
| 8 | Emcure Pharmaceuticals Limited | 4.37% |
| 9 | Max Healthcare Institute Limited | 3.80% |
| 10 | Fortis Healthcare Limited | 3.01% |